Government commitment and regulation of prescription drugs

Health Affairs

Volumn 22, Issue 3, 2003, Pages 46-48

  Frank, Richard G ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; COST; COST CONTROL; DRUG COST; DRUG INDUSTRY; ECONOMICS; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HUMAN; LEGAL ASPECT; MEDICAID; MEDICARE; NOTE; PRESCRIPTION; PUBLIC RELATIONS; UNITED STATES;

AGED; COST CONTROL; COST SHARING; DRUG COSTS; DRUG INDUSTRY; FEDERAL GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE RATIONING; HEALTH CARE SECTOR; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERINSTITUTIONAL RELATIONS; MEDICAID; MEDICARE; PRESCRIPTIONS, DRUG; UNITED STATES;

EID: 0038387476     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.22.3.46     Document Type: Review

References (13)

1. J. DiMasi et al., "The Cost of New Drugs," Journal of Health Economics 22, no. 2 (2003): 151-186;
2. and R.G. Frank, "The Cost of New Drugs" (editorial), Journal of Health Economics 22, no. 2 (2003): 325-330.
3. National Institute of Health Care Management Research and Educational Foundation, Prescription Drug Expenditures in 2001: Another Year of Escalating Costs (Washington: NIHCM, May 2002).
4. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, 2000 Report to the Nation: Improving Public Health through Human Drugs (Washington: FDA, 2001).
5. Figures for industry spending on R&D and on advertising are from Henry J. Kaiser Family Foundation, Prescription Drug Trends: A Chartbook Update (Menlo Park, Calif.: Kaiser Family Foundation, November 2001).
6. U.S. Congress, Office of Technology Assessment, Pharmaceutical R&D: Costs, Risks, and Rewards (Washington: U.S. GPO, 1993).
7. See Public Citizen, America's Other Drug Problem: A Briefing Book on the Rx Drug Debate, 2002, www.citizen.org/rxfacts (18 March 2003).
8. R.G. Frank, "Prescription Drug Prices: Why Do Some People Pay More than Others?" Health Affairs (Mar/Apr 2002): 115-128.
9. U.S. Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study (Washington: FTC, July 2002).
10. F.M. Scherer, "The Pharmaceutical Industry," in Handbook of Health Economics, ed. A.J. Culyer and J.P. Newhouse (Amsterdam: North-Holland, 2000).
11. Henry J. Kaiser Family Foundation, Prescription Drug Trends: A Chartbook Update, November 2001, www.kff.org/content/2001/3112/RxChartbook.pdf (18 March 2003).
12. J. Stiglitz, "The Private Uses of the Public Interests: Incentives and Institutions," Journal of Economic Perspectives 12, no. 2 (1998): 3-22.
13. P. Pierson, "The Limits of Design: Explaining Institutional Origins and Change," Governance 13, no. 4 (2000): 475-499.